EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex Pharmaceuticals ... it might even be able to push this forward into a phase 3 study in the next year or so. It is important to note that LSR is a form of peripheral neuropathic pain.

The company's strong performance in CF has driven impressive growth, but investors are closely watching its efforts to diversify into new therapeutic areas. This analysis examines Vertex's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Price Targets: Understanding forecasts, analysts offer estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...

For valuable insights into Vertex Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions ...

While analysts expect a gradual ramp-up in revenue recognition, CASGEVY represents Vertex's expansion into the promising field of gene therapy. Vertex's strong operational execution has impressed ...

While analysts expect a gradual ramp-up in revenue recognition, CASGEVY represents Vertex's expansion into the promising field of gene therapy. Vertex's strong operational execution has impressed ...

Vertex's stock performance in the near term may be influenced by the outcome of the FDA's decision and the subsequent market reception of the drug. For deeper insights into Vertex's financial health ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...